Temozolomide (NSC 362856), DNA Alkylator

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.

Current and future developments in the use of temozolomide for the treatment of brain tumours - The Lancet Oncology

A) Sites of alkylation on the various bases in the DNA. Temozolomide

PDF) Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

DNA Damage/DNA Repair - BioCrick

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture

Temozolomide (NSC 362856), DNA Alkylator

T1178-50mg Temozolomide [85622-93-1] Hexabiogen

Where to Buy 85622-93-1

Temozolomide (NSC 362856), DNA Alkylator

Temozolomide (NSC 362856), DNA Alkylator

Diagram showing how alkylating drugs temozolomide (TMZ), nimustine

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Frontiers An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

Biomedicines, Free Full-Text

Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy - ScienceDirect